

JENKINS & WILSON, P.A.

PATENT ATTORNEYS

SUITE 1400 UNIVERSITY TOWER

3100 TOWER BOULEVARD

DURHAM, NORTH CAROLINA 27707

TELEPHONE (919) 493-8000

FACSIMILE (919) 419-0383

WEBSITE

JENKINSANDWILSON.COM

RALEIGH OFFICE

NCSU CENTENNIAL CAMPUS

VENTURE II SUITE 400

920 MAIN CAMPUS DRIVE

RALEIGH, NORTH CAROLINA 27606

TELEPHONE (919) 424-3710

FACSIMILE (919) 424-3711

RICHARD E. JENKINS  
JEFFREY L. WILSON  
ARLES A. TAYLOR, JR.

JENNIFER L. SKORD  
DAVID P. GLOEKLER  
GREGORY A. HUNT

JOHN A. LAMERDIN, PH.D. (PATENT AGENT)


DAVID P. STITZEL (PATENT AGENT)

JULIE A. BROADUS, PH.D. (PATENT AGENT)

E. ERIC MILLS, P.E. (PATENT AGENT)

August 15, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. on 8-15-01

  
Amy J. Martin  
Date of Signature 8-15-01

Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/835,976 for PURIFIED AND ISOLATED POTASSIUM-CHLORIDE COTRANSPORTER NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND SCREENING METHODS USING SAME  
Our File No. 1242/26/2

Sir:

Please find enclosed in connection with the subject U.S. patent application the following documents:

1. Information Disclosure Statement (2 pages);
2. Form PTO/SB/08A (in duplicate);
3. Copies of cited references (13 references);
4. A return-receipt postcard to be returned to us with the U.S. Patent and Trademark Office filing stamp thereon.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.



Arles A. Taylor, Jr.

Registration No. 39,395

Customer No. Bar Code Label:




25297

PATENT TRADEMARK OFFICE

AAT/ajm

Enclosures



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 8-15-01

Amy J. Martin  
Date of Signature 8-15-01

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mount et al.

**Serial No.: 09/835,976**

Group Art Unit: Not Assigned

Filed: April 16, 2001

Docket No.: 1242/26/2

Confirmation No.: Not Assigned

For: PURIFIED AND ISOLATED POTASSIUM-CHLORIDE COTRANSPORTER  
NUCLEIC ACIDS AND POLYPEPTIDES AND THERAPEUTIC AND  
SCREENING METHODS USING SAME

\*\*\*\*\*

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the following references. Form PTO/SB/08A is attached hereto. Copies of the references are also enclosed. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

U.S. Patent No. 4,895,807 to Cherksey discloses a membrane channel protein and related therapeutic compounds.

U.S. Patent No. 5,166,162 to Masreel et al. discloses pyridylsulfonylurea and pyridylsulfonylthiourea compounds.

U.S. Patent No. 5,410,031 to Wright et al. discloses a nucleoside cotransporter protein cDNA.

U.S. Patent No. 5,441,875 to Hediger discloses a urea transporter polypeptide.

U.S. Patent No. 5,668,157 to Humphrey et al. discloses cyanoguanidines as k-channel blockers.

U.S. Patent No. 5,856,338 to Brendel et al. discloses sulfonamide-substituted compounds, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparation comprising them.

Canadian Patent No. 2,037,189 to Masreel et al. discloses new 4-(cycloalkylamino)pyridylsulphonyl (thio) urea derivatives for treating arterial hypertension and cerebral oedema.

European Patent Application No. 0 560 232 A1 to DeSouza et al. discloses novel 7-aminolabdanes, a process for their preparation and their use as pharmaceutical agents.

PCT International Application No. WO 96/17602 to Brandt et al. discloses a method for enhancing outflow of aqueous humor in treatment of glaucoma.

PCT International Application No. WO 96/34288 to Ni et al. discloses a human brain sodium-dependent inorganic phosphate cotransporter.

PCT International Application No. WO 98/29431 to Lifton et al. discloses a method to diagnose and treat pathological conditions resulting from deficient ion transport.

PCT International Application No. WO 98/37198 to Lal et al. discloses a human sodium-dependent phosphate cotransporter.

PCT International Application No. WO 98/53067 to Bevensee et al. discloses *NBC*, a gene that encodes a member of the bicarbonate transporter family of proteins.

Early passage of the subject application to issue is earnestly solicited.

Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any deficiencies of payment associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS & WILSON, P.A.

Date: August 15, 2001  
Suite 1400 University Tower  
3100 Tower Boulevard  
Durham, North Carolina 27707  
Telephone: (919) 493-8000  
Facsimile: (919) 419-0383

By: Arles A. Taylor, Jr.  
Arles A. Taylor, Jr.  
Registration No. 39,395

Customer No. Bar Code Label:



1242/36/2 AAT/ajm

25297

PATENT TRADEMARK OFFICE

Enclosures